Korea Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation issues that come along this expensive and complex technology and shows how stem cell therapies can be better included in…
Korea Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of revenues in the USA following its approval. Mr Lee also clarifies Korea’s position within gene therapy R&D and explains Kolon’s…
Korea Dr BG Rhee, CEO of SCM Lifescience discusses their patented proprietary subfraction technology to extract high purity cell cultures, and the impact this will have on the efficacy, cell differentiation ability, and cost of stem cell treatments. Dr Rhee also provides his assessment of the regulatory framework for stem cells…
UK A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO, Janet Downie, presents the company’s expansion plans and talks about new areas worth pursuing as well as the advantages of…
UK Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James Noble, shares Adaptimmune’s story and explains why regulatory support is essential in a field as complex and novel as T-Cell…
UK After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR T therapies towards the clinic. Developing allogeneic variants of Gamma Delta T Cells, TC BioPharm aims to become a global…
China In this unique interview, Dr. David Peng, CEO of Medical Excellence International (China), shares the company´s foundations, its key milestones as well as its two unique membership programs. He further reveals how Medical Excellence is committed to connect its members to the best medical institutions and physicians around the world…
UK Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international collaboration and Brexit. Most likely, the UK is the best environment for putting forward trials that are properly…
Latvia Inese Bolmane, business development manager at Latvian stem cell bank Cilmes Šūnu Banka, explains the basic rationale behind stem cell banking and what differentiates Cilmes Šūnu Banka from the competition. Could you please start by introducing the Cilmes Šūnu Banka? “One positive by-product of increased competition is that our competitors…
Ireland Dr. Terry McWade, CEO of Valitacell, discusses the founding of his company, the ground-breaking technology they are producing, and how this technology can help to bring new biologic medications to market faster and more cost-effectively. Having just won the Seedcorn Competition as well as being placed on the list of…
France Marc de Garidel reveals how 2015 has been Ipsen’s best year since becoming publicly traded, marked by their take-off in the US, and how in 2016 the US will overtake France to become their number one affiliate. Mr de Garidel also explains Ipsen’s key growth drivers for the next five…
Pharma Pharmaceuticals Stéphane Bouchard reveals why BD’s pharmaceutical systems centre of excellence is based in France; BD’s increased strength in medical devices following the acquisition of CareFusion in 2015; and why cooperation and transparency between medical device and pharmaceutical companies is crucial. What role can BD, as one of the world’s leading companies specializing in medical devices,…
See our Cookie Privacy Policy Here